We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research

By LabMedica International staff writers
Posted on 04 Nov 2026

Breast cancer is commonly classified by hormone receptor and HER2 status, yet patients within the same category can have very different clinical responses. More...

Transcriptomic profiling can reveal gene-expression patterns that standard pathology may not fully capture, creating a need for molecular tools that better stratify tumors for precision oncology. Building on this approach, new findings show that a large transcriptomic atlas can uncover previously unrecognized breast cancer subtypes with distinct outcomes and treatment sensitivities.

Vanderbilt-Ingram Cancer Center generated a molecular map of breast cancer by integrating transcriptomic data from more than 7,600 tumors across 22 independent studies. The atlas is based on the tumor transcriptome, the complete set of RNA molecules produced by a tumor. It groups breast cancers into interconnected clusters that share molecular features, treatment responses, and clinical outcomes.

The researchers adapted computational approaches originally developed for single-cell genomics to address differences among datasets generated across studies, sequencing platforms, and analytical methods. The resulting map resembles an archipelago, with related tumor populations forming distinct molecular “islands.” The team also created a tool that can assign tumors to subtypes using standard bulk RNA sequencing data for future research studies and clinical trials.

The study, published Nov. 3 in Cell Reports Medicine, found substantial biological diversity within traditional breast cancer categories. Estrogen receptor-low tumors behaved more like estrogen receptor-negative disease, while subsets of human epidermal growth factor receptor 2 (HER2)-positive tumors appeared most dependent on HER2 signaling. The atlas also identified a hidden neuroendocrine form associated with worse outcomes after standard chemo-endocrine therapy, as well as an aggressive basal-luminal progenitor subtype of triple-negative breast cancer with potential therapeutic vulnerabilities.

The work involved Vanderbilt-Ingram Cancer Center, Vanderbilt Health, and the Department of Medicine at Vanderbilt Health. The researchers stated that prospective testing is needed to determine whether treatment decisions guided by transcriptional subtypes improve patient outcomes. They also indicated that the computational approach could be applied to transcriptomic, proteomic, and other large-scale molecular datasets across a wide range of diseases.

“The breast cancer atlas provides an unprecedented view of the disease’s molecular diversity and reveals distinct tumor populations associated with different clinical outcomes, biological characteristics and therapeutic vulnerabilities. By analyzing thousands of tumors together, we uncovered previously hidden forms of breast cancer that differ in prognosis, biology and treatment sensitivity,” said Brian Lehmann, PhD, Research Associate Professor of Medicine at Vanderbilt Health.

“The next critical step is prospective testing to determine whether treatment decisions guided by these transcriptional subtypes improve patient outcomes. Our goal is to match patients to therapies based on the biology of their tumors. This atlas provides both a road map and a practical framework for achieving that vision,” added Lehmann.

Related Links

Vanderbilt-Ingram Cancer Center 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The MIRAM GAGome Kit quantifies urine CS disaccharides by UHPLC-MS/MS, supporting exploratory and translational research across disease areas. (Photo courtesy of Elypta)

Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction

Cancer risk stratification in healthy adults often relies on established factors such as age and smoking history. However, several cancers highlighted in the study, including pancreatic, kidney, and brain... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.